Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + Paclitaxel in metastatic triple-negative breast cancer
NCT03997123Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2019
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial in triple-negative breast cancer (TNBC) comparing Capivasertib + Paclitaxel with Placebo + Paclitaxel (2 arms). Primary endpoint: Overall Survival at 42 months. Started Jun 2019; status: active, not recruiting.
02
Drugs
capivasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03997123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03997123.